Parameters predicting COVID-19-induced myocardial injury and mortality.
Aged
Betacoronavirus
/ isolation & purification
Biomarkers
/ analysis
COVID-19
Coronavirus Infections
/ complications
Female
Germany
/ epidemiology
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Myocardial Reperfusion Injury
/ diagnosis
Myocardium
/ metabolism
Pandemics
Pneumonia, Viral
/ complications
Prognosis
Risk Assessment
/ methods
Risk Factors
SARS-CoV-2
Survival Rate
CD8
COVID-19
Monocyte
Pericardial effusion
SARS-CoV-2
Treg
Journal
Life sciences
ISSN: 1879-0631
Titre abrégé: Life Sci
Pays: Netherlands
ID NLM: 0375521
Informations de publication
Date de publication:
01 Nov 2020
01 Nov 2020
Historique:
received:
20
08
2020
revised:
01
09
2020
accepted:
03
09
2020
pubmed:
13
9
2020
medline:
11
11
2020
entrez:
12
9
2020
Statut:
ppublish
Résumé
Clinical manifestations of COVID-19 affect many organs, including the heart. Cardiovascular disease is a dominant comorbidity and prognostic factors predicting risk for critical courses are highly needed. Moreover, immunomechanisms underlying COVID-induced myocardial damage are poorly understood. To elucidate prognostic markers to identify patients at risk. Only patients with pericardial effusion (PE) developed a severe disease course, and those who died could be identified by a high CD8/Treg/monocyte ratio. Ten out of 19 COVID-19 patients presented with PE, 7 (78%) of these had elevated APACHE-II mortality risk-score, requiring mechanical ventilation. At admission, PE patients showed signs of systemic and cardiac inflammation in NMR and impaired cardiac function as detected by transthoracic echocardiography (TTE), whereas parameters of myocardial injury e.g. high sensitive troponin-t (hs-TnT) were not yet increased. During the course of disease, hs-TnT rose in 8 of the PE-patients above 16 ng/l, 7 had to undergo ventilatory therapy and 4 of them died. FACS at admission showed in PE patients elevated frequencies of CD3 PE predicts cardiac injury in COVID-19 patients. Therefore, TTE should be performed at admission. Immunological parameters for dysfunctional antiviral immunity, such as the CD8/Treg/monocyte ratio used here, supports risk assessment by predicting poor prognosis.
Identifiants
pubmed: 32918975
pii: S0024-3205(20)31153-X
doi: 10.1016/j.lfs.2020.118400
pmc: PMC7480277
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118400Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
Eur Heart J. 2020 Jun 7;41(22):2070-2079
pubmed: 32391877
N Engl J Med. 2020 Aug 6;383(6):590-592
pubmed: 32402155
Circ Cardiovasc Imaging. 2020 May;13(5):e010897
pubmed: 32397816
Life Sci. 2020 Sep 15;257:118058
pubmed: 32653518
Hum Immunol. 2000 Jan;61(1):74-81
pubmed: 10658980
Blood Cells Mol Dis. 2020 Jul;83:102437
pubmed: 32325421
Lancet. 2020 May 9;395(10235):1516
pubmed: 32334650
Life Sci. 2020 Jul 15;253:117723
pubmed: 32360126
Lancet Respir Med. 2020 May;8(5):e27
pubmed: 32203708
JACC Basic Transl Sci. 2020 Apr 10;5(5):537-542
pubmed: 32292847
Circulation. 2020 Sep 15;142(11):1123-1125
pubmed: 32689809
Cardiovasc Res. 2020 Aug 1;116(10):1666-1687
pubmed: 32352535
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
JAMA Cardiol. 2020 Nov 1;5(11):1265-1273
pubmed: 32730619
Nat Rev Immunol. 2020 Jun;20(6):355-362
pubmed: 32376901
JAMA Cardiol. 2020 Nov 1;5(11):1281-1285
pubmed: 32730555